-

Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021, at 3:00 p.m. Eastern Time.

The conference will be held virtually. A live webcast of Acadia’s presentation will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through September 12, 2021.

About Acadia Pharmaceuticals

Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn and Twitter.

Contacts

Media Contact:
Acadia Pharmaceuticals Inc.
Eric Endicott
(858) 914-7161
media@acadia-pharm.com

Investor Contact:
Acadia Pharmaceuticals Inc.
Mark Johnson, CFA
(858) 261-2771
ir@acadia-pharm.com

Acadia Pharmaceuticals Inc.

NASDAQ:ACAD

Release Versions

Contacts

Media Contact:
Acadia Pharmaceuticals Inc.
Eric Endicott
(858) 914-7161
media@acadia-pharm.com

Investor Contact:
Acadia Pharmaceuticals Inc.
Mark Johnson, CFA
(858) 261-2771
ir@acadia-pharm.com

More News From Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18–22, 2026 in Chicago, IL. The Company will present real-world data from a sub-group analysis of the ongoing, Phase 4, prospective, observational, open-label LOTUS study evaluating the benefits and tolerability of DAYBUE® (trofinetide) in adults w...

Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia’s website, acadia.com under the investors section and will be archived there until August 15, 2026. The conference call...

Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide, is now broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. The new formulation, approved by the U.S. Food and Drug Administration (FDA) in December 2025, is bioequivalent to the original DAYBUE® oral solution, deliverin...
Back to Newsroom